AIC
PTGX icon

AWM Investment Company’s Protagonist Therapeutics PTGX Stock Holding History

AWM Investment Company’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-177,212
Closed -$3.69M – 98
2017
Q4 		$3.69M Buy
+177,212
New +$3.14M 0.72% 45

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AWM Investment Company's PTGX Position: Q1 2018 in Review

AWM Investment Company sold out of Protagonist Therapeutics (PTGX) in Q1 2018, closing a stake of 177,212 shares — an estimated $3.69M sold.

AWM Investment Company first reported a position in PTGX in Q4 2017 and held it in 1 quarter. The position peaked at $3.69M in Q4 2017. 70 funds tracked by Wall St. Rank hold PTGX as of Q1 2018.

  • AWM Investment Company reported no remaining Protagonist Therapeutics position as of Q1 2018 after selling out during the quarter.
  • AWM Investment Company sold 177,212 Protagonist Therapeutics shares in Q1 2018, an estimated $3.69M.
  • AWM Investment Company first reported a position in Protagonist Therapeutics in Q4 2017 and held it in 1 quarter.
  • AWM Investment Company's Protagonist Therapeutics position peaked at $3.69M in Q4 2017.
  • 70 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2018.

Based on AWM Investment Company's 13F filing for Q1 2018, filed 10 May 2018.